Skip to main content

Advertisement

SpringerLink
Log in

Diverse immune evasion strategies by human cytomegalovirus

  • Immunology at Mount Sinai
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Members of the Herpesviridae family have the capacity to undergo both lytic and latent infection to establish a lifelong relationship with their host. Following primary infection, human cytomegalovirus (HCMV) can persist as a subclinical, recurrent infection for the lifetime of an individual. This quiescent portion of its life cycle is termed latency and is associated with periodic bouts of reactivation during times of immunosuppression, inflammation, or stress. In order to exist indefinitely and establish infection, HCMV encodes a multitude of immune modulatory mechanisms devoted to escaping the host antiviral response. HCMV has become a paradigm for studies of viral immune evasion of antigen presentation by both major histocompatibility complex (MHC) class I and II molecules. By restricting the presentation of viral antigens during both productive and latent infection, HCMV limits elimination by the human immune system. This review will focus on understanding how the virus manipulates the pathways of antigen presentation in order to modulate the host response to infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mocarski ES, Shenk T, Pass RF. Cytomegaloviruses. In: Howley DMKPM, editor. Fields virology. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007.

    Google Scholar 

  2. Slobedman B, Cao JZ, Avdic S, Webster B, McAllery S, Cheung AK, et al. Human cytomegalovirus latent infection and associated viral gene expression. Futur Microbiol. 2010;5(6):883–900. doi:10.2217/fmb.10.58.

    CAS  Google Scholar 

  3. Sinclair J. Human cytomegalovirus: latency and reactivation in the myeloid lineage. J Clin Virol. 2008;41(3):180–5. doi:10.1016/j.jcv.2007.11.014.

    PubMed  CAS  Google Scholar 

  4. Gibson W. Structure and formation of the cytomegalovirus virion. Curr Top Microbiol Immunol. 2008;325:187–204.

    PubMed  CAS  Google Scholar 

  5. Compton T, Nowlin DM, Cooper NR. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology. 1993;193(2):834–41. doi:10.1006/viro.1993.1192.

    PubMed  CAS  Google Scholar 

  6. Isaacson MK, Juckem LK, Compton T. Virus entry and innate immune activation. Curr Top Microbiol Immunol. 2008;325:85–100.

    PubMed  CAS  Google Scholar 

  7. Adler B, Scrivano L, Ruzcics Z, Rupp B, Sinzger C, Koszinowski U. Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J Gen Virol. 2006;87(Pt 9):2451–60. doi:10.1099/vir.0.81921-0.

    PubMed  CAS  Google Scholar 

  8. Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A, et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol. 2004;78(18):10023–33. doi:10.1128/JVI.78.18.10023-10033.2004.

    PubMed  CAS  Google Scholar 

  9. Gerna G, Percivalle E, Lilleri D, Lozza L, Fornara C, Hahn G, et al. Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol. 2005;86(Pt 2):275–84. doi:10.1099/vir.0.80474-0.

    PubMed  CAS  Google Scholar 

  10. Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, Johnson DC. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol. 2006;80(2):710–22. doi:10.1128/JVI.80.2.710-722.2006.

    PubMed  CAS  Google Scholar 

  11. Ryckman BJ, Rainish BL, Chase MC, Borton JA, Nelson JA, Jarvis MA, et al. Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol. 2008;82(1):60–70. doi:10.1128/JVI.01910-07.

    PubMed  CAS  Google Scholar 

  12. Straschewski S, Patrone M, Walther P, Gallina A, Mertens T, Frascaroli G. Protein pUL128 of human cytomegalovirus is necessary for monocyte infection and blocking of migration. J Virol. 2011;85(10):5150–8. doi:10.1128/JVI.02100-10.

    PubMed  CAS  Google Scholar 

  13. Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA. 2005;102(50):18153–8. doi:10.1073/pnas.0509201102.

    PubMed  CAS  Google Scholar 

  14. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol. 1996;70(1):78–83.

    PubMed  CAS  Google Scholar 

  15. Dolan A, Cunningham C, Hector RD, Hassan-Walker AF, Lee L, Addison C, et al. Genetic content of wild-type human cytomegalovirus. J Gen Virol. 2004;85(Pt 5):1301–12.

    PubMed  CAS  Google Scholar 

  16. Vanarsdall AL, Chase MC, Johnson DC. Human cytomegalovirus glycoprotein gO complexes with gH/gL, promoting interference with viral entry into human fibroblasts but not entry into epithelial cells. J Virol. 2011;85(22):11638–45. doi:10.1128/JVI.05659-11.

    PubMed  CAS  Google Scholar 

  17. Lopper M, Compton T. Coiled-coil domains in glycoproteins B and H are involved in human cytomegalovirus membrane fusion. J Virol. 2004;78(15):8333–41. doi:10.1128/JVI.78.15.8333-8341.2004.

    PubMed  CAS  Google Scholar 

  18. Ogawa-Goto K, Tanaka K, Gibson W, Moriishi E, Miura Y, Kurata T, et al. Microtubule network facilitates nuclear targeting of human cytomegalovirus capsid. J Virol. 2003;77(15):8541–7.

    PubMed  CAS  Google Scholar 

  19. Cherrington JM, Mocarski ES. Human cytomegalovirus ie1 transactivates the alpha promoter-enhancer via an 18-base-pair repeat element. J Virol. 1989;63(3):1435–40.

    PubMed  CAS  Google Scholar 

  20. Meier JL, Stinski MF. Effect of a modulator deletion on transcription of the human cytomegalovirus major immediate-early genes in infected undifferentiated and differentiated cells. J Virol. 1997;71(2):1246–55.

    PubMed  CAS  Google Scholar 

  21. Kalejta RF. Tegument proteins of human cytomegalovirus. Microbiol Mol Biol Rev. 2008;72(2):249–65. doi:10.1128/MMBR.00040-07. table of contents.

    PubMed  CAS  Google Scholar 

  22. Gant TM, Wilson KL. Nuclear assembly. Annu Rev Cell Dev Biol. 1997;13:669–95. doi:10.1146/annurev.cellbio.13.1.669.

    PubMed  CAS  Google Scholar 

  23. Radsak KD, Brucher KH, Georgatos SD. Focal nuclear envelope lesions and specific nuclear lamin A/C dephosphorylation during infection with human cytomegalovirus. Eur J Cell Biol. 1991;54(2):299–304.

    PubMed  CAS  Google Scholar 

  24. Eickmann M, Gicklhorn D, Radsak K. Glycoprotein trafficking in virion morphogenesis. In: Reddehase M, Lemmermann N, editors. Cytomegaloviruses: molecular biology and immunology. Wymondham: Caister Academic Press; 2006. p. 245–64.

    Google Scholar 

  25. Sanchez V, Angeletti PC, Engler JA, Britt WJ. Localization of human cytomegalovirus structural proteins to the nuclear matrix of infected human fibroblasts. J Virol. 1998;72(4):3321–9.

    PubMed  CAS  Google Scholar 

  26. Trus BL, Gibson W, Cheng N, Steven AC. Capsid structure of simian cytomegalovirus from cryoelectron microscopy: evidence for tegument attachment sites. J Virol. 1999;73(3):2181–92.

    PubMed  CAS  Google Scholar 

  27. Liu W, Zhao Y, Biegalke B. Analysis of human cytomegalovirus US3 gene products. Virology. 2002;301(1):32–42.

    PubMed  CAS  Google Scholar 

  28. Loewendorf A, Benedict CA. Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything. J Intern Med. 2010;267(5):483–501. doi:10.1111/j.1365-2796.2010.02220.x.

    PubMed  CAS  Google Scholar 

  29. Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. J Gen Virol. 2006;87(Pt 7):1763–79. doi:10.1099/vir.0.81891-0.

    PubMed  CAS  Google Scholar 

  30. Goodrum FD, Jordan CT, High K, Shenk T. Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. Proc Natl Acad Sci USA. 2002;99(25):16255–60. doi:10.1073/pnas.252630899.

    PubMed  CAS  Google Scholar 

  31. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci USA. 1998;95(7):3937–42.

    PubMed  CAS  Google Scholar 

  32. Minton EJ, Tysoe C, Sinclair JH, Sissons JG. Human cytomegalovirus infection of the monocyte/macrophage lineage in bone marrow. J Virol. 1994;68(6):4017–21.

    PubMed  CAS  Google Scholar 

  33. Reeves MB, MacAry PA, Lehner PJ, Sissons JG, Sinclair JH. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc Natl Acad Sci USA. 2005;102(11):4140–5. doi:10.1073/pnas.0408994102.

    PubMed  CAS  Google Scholar 

  34. Drew WL. Diagnosis of cytomegalovirus infection. Rev Infect Dis. 1988;10(Suppl 3):S468–76.

    PubMed  Google Scholar 

  35. Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis. 1990;12(Suppl 7):S754–66.

    PubMed  Google Scholar 

  36. Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med. 2006;259(3):219–46. doi:10.1111/j.1365-2796.2006.01618.x.

    PubMed  CAS  Google Scholar 

  37. Adler SP. Transfusion-associated cytomegalovirus infections. Rev Infect Dis. 1983;5(6):977–93.

    PubMed  CAS  Google Scholar 

  38. Tolpin MD, Stewart JA, Warren D, Mojica BA, Collins MA, Doveikis SA, et al. Transfusion transmission of cytomegalovirus confirmed by restriction endonuclease analysis. J Pediatr. 1985;107(6):953–6.

    PubMed  CAS  Google Scholar 

  39. Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, Prober CG. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr. 1981;98(2):281–7.

    PubMed  CAS  Google Scholar 

  40. Jordan MC. Latent infection and the elusive cytomegalovirus. Rev Infect Dis. 1983;5(2):205–15.

    PubMed  CAS  Google Scholar 

  41. de Graan-Hentzen YC, Gratama JW, Mudde GC, Verdonck LF, Houbiers JG, Brand A, et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion. 1989;29(9):757–60.

    PubMed  Google Scholar 

  42. Stanier P, Taylor DL, Kitchen AD, Wales N, Tryhorn Y, Tyms AS. Persistence of cytomegalovirus in mononuclear cells in peripheral blood from blood donors. BMJ. 1989;299(6704):897–8.

    PubMed  CAS  Google Scholar 

  43. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol. 1991;72(Pt 9):2059–64.

    PubMed  CAS  Google Scholar 

  44. Mendelson M, Monard S, Sissons P, Sinclair J. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J Gen Virol. 1996;77(Pt 12):3099–102.

    PubMed  CAS  Google Scholar 

  45. Slobedman B, Mocarski ES. Quantitative analysis of latent human cytomegalovirus. J Virol. 1999;73(6):4806–12.

    PubMed  CAS  Google Scholar 

  46. Bolovan-Fritts CA, Mocarski ES, Wiedeman JA. Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood. 1999;93(1):394–8.

    PubMed  CAS  Google Scholar 

  47. Jarvis MA, Fish KN, Soderberg-Naucler C, Streblow DN, Meyers HL, Thomas G, et al. Retrieval of human cytomegalovirus glycoprotein B from cell surface is not required for virus envelopment in astrocytoma cells. J Virol. 2002;76(10):5147–55.

    PubMed  CAS  Google Scholar 

  48. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327(5963):291–5. doi:327/5963/291.

    PubMed  CAS  Google Scholar 

  49. Kumagai Y, Akira S. Identification and functions of pattern-recognition receptors. J Allergy Clin Immunol. 2010;125(5):985–92. doi:10.1016/j.jaci.2010.01.058.

    PubMed  CAS  Google Scholar 

  50. Hirano M, Das S, Guo P, Cooper MD. The evolution of adaptive immunity in vertebrates. Adv Immunol. 2011;109:125–57. doi:10.1016/B978-0-12-387664-5.00004-2.

    PubMed  CAS  Google Scholar 

  51. Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. Immunity. 2011;35(2):161–8. doi:10.1016/j.immuni.2011.07.010.

    PubMed  CAS  Google Scholar 

  52. Sheridan BS, Lefrancois L. Regional and mucosal memory T cells. Nat Immunol. 2011;12(6):485–91.

    PubMed  CAS  Google Scholar 

  53. Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;11(12):823–36. doi:10.1038/nri3084.

    PubMed  CAS  Google Scholar 

  54. Kushwah R, Hu J. Complexity of dendritic cell subsets and their function in the host immune system. Immunology. 2011;133(4):409–19. doi:10.1111/j.1365-2567.2011.03457.x.

    PubMed  CAS  Google Scholar 

  55. Nace G, Evankovich J, Eid R, Tsung A. Dendritic cells and damage-associated molecular patterns: endogenous danger signals linking innate and adaptive immunity. J Innate Immun. 2012;4(1):6–15. doi:10.1159/000334245.

    PubMed  CAS  Google Scholar 

  56. Rocha N, Neefjes J. MHC class II molecules on the move for successful antigen presentation. EMBO J. 2008;27(1):1–5. doi:10.1038/sj.emboj.7601945.

    PubMed  CAS  Google Scholar 

  57. Chapman DC, Williams DB. ER quality control in the biogenesis of MHC class I molecules. Semin Cell Dev Biol. 2010;21(5):512–9. doi:10.1016/j.semcdb.2009.12.013.

    PubMed  CAS  Google Scholar 

  58. Kurts C, Robinson BW, Knolle PA. Cross-priming in health and disease. Nat Rev Immunol. 2010;10(6):403–14. doi:10.1038/nri2780.

    PubMed  CAS  Google Scholar 

  59. Kracker S, Durandy A. Insights into the B cell specific process of immunoglobulin class switch recombination. Immunol Lett. 2011;138(2):97–103. doi:10.1016/j.imlet.2011.02.004.

    PubMed  CAS  Google Scholar 

  60. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. Viral subversion of the immune system. Annu Rev Immunol. 2000;18:861–926. doi:10.1146/annurev.immunol.18.1.861.

    PubMed  CAS  Google Scholar 

  61. Barnes PD, Grundy JE. Down-regulation of the class I HLA heterodimer and beta 2-microglobulin on the surface of cells infected with cytomegalovirus. J Gen Virol. 1992;73(Pt 9):2395–403.

    PubMed  CAS  Google Scholar 

  62. Beersma MF, Bijlmakers MJ, Ploegh HL. Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. J Immunol. 1993;151(9):4455–64.

    PubMed  CAS  Google Scholar 

  63. del Val M, Hengel H, Hacker H, Hartlaub U, Ruppert T, Lucin P, et al. Cytomegalovirus prevents antigen presentation by blocking the transport of peptide-loaded major histocompatibility complex class I molecules into the medial-Golgi compartment. J Exp Med. 1992;176(3):729–38.

    PubMed  Google Scholar 

  64. Gilbert MJ, Riddell SR, Li CR, Greenberg PD. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol. 1993;67(6):3461–9.

    PubMed  CAS  Google Scholar 

  65. Yamashita Y, Shimokata K, Mizuno S, Yamaguchi H, Nishiyama Y. Down-regulation of the surface expression of class I MHC antigens by human cytomegalovirus. Virology. 1993;193(2):727–36. doi:10.1006/viro.1993.1181.

    PubMed  CAS  Google Scholar 

  66. Jones TR, Hanson LK, Sun L, Slater JS, Stenberg RM, Campbell AE. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J Virol. 1995;69(8):4830–41.

    PubMed  CAS  Google Scholar 

  67. Ahn K, Angulo A, Ghazal P, Peterson PA, Yang Y, Fruh K. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad Sci USA. 1996;93(20):10990–5.

    PubMed  CAS  Google Scholar 

  68. Jones TR, Wiertz EJ, Sun L, Fish KN, Nelson JA, Ploegh HL. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci USA. 1996;93(21):11327–33.

    PubMed  CAS  Google Scholar 

  69. Lee S, Park B, Ahn K. Determinant for endoplasmic reticulum retention in the luminal domain of the human cytomegalovirus US3 glycoprotein. J Virol. 2003;77(3):2147–56.

    PubMed  CAS  Google Scholar 

  70. Zhao Y, Biegalke BJ. Functional analysis of the human cytomegalovirus immune evasion protein, pUS3 (22 kDa). Virology. 2003;315(2):353–61.

    PubMed  CAS  Google Scholar 

  71. Park B, Kim Y, Shin J, Lee S, Cho K, Fruh K, et al. Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Immunity. 2004;20(1):71–85.

    PubMed  CAS  Google Scholar 

  72. Jun Y, Kim E, Jin M, Sung HC, Han H, Geraghty DE, et al. Human cytomegalovirus gene products US3 and US6 down-regulate trophoblast class I MHC molecules. J Immunol. 2000;164(2):805–11.

    PubMed  CAS  Google Scholar 

  73. Noriega VM, Tortorella D. Human cytomegalovirus-encoded immune modulators partner to downregulate major histocompatibility complex class I molecules. J Virol. 2009;83(3):1359–67. doi:10.1128/JVI.01324-08.

    PubMed  CAS  Google Scholar 

  74. Hegde NR, Tomazin RA, Wisner TW, Dunn C, Boname JM, Lewinsohn DM, et al. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation. J Virol. 2002;76(21):10929–41.

    PubMed  CAS  Google Scholar 

  75. Jones TR, Sun L. Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. J Virol. 1997;71(4):2970–9.

    PubMed  CAS  Google Scholar 

  76. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell. 1996;84(5):769–79.

    PubMed  CAS  Google Scholar 

  77. Wiertz EJ, Tortorella D, Bogyo M, Yu J, Mothes W, Jones TR, et al. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature. 1996;384(6608):432–8. doi:10.1038/384432a0.

    PubMed  CAS  Google Scholar 

  78. Smith MH, Ploegh HL, Weissman JS. Road to ruin: targeting proteins for degradation in the endoplasmic reticulum. Science. 2011;334(6059):1086–90. doi:10.1126/science.1209235.

    PubMed  CAS  Google Scholar 

  79. Lilley BN, Tortorella D, Ploegh HL. Dislocation of a type I membrane protein requires interactions between membrane-spanning segments within the lipid bilayer. Mol Biol Cell. 2003;14(9):3690–8. doi:10.1091/mbc.E03-03-0192.

    PubMed  CAS  Google Scholar 

  80. Noriega VM, Tortorella D. A bipartite trigger for dislocation directs the proteasomal degradation of an endoplasmic reticulum membrane glycoprotein. J Biol Chem. 2008;283(7):4031–43. doi:10.1074/jbc.M706283200.

    PubMed  CAS  Google Scholar 

  81. Oresic K, Noriega V, Andrews L, Tortorella D. A structural determinant of human cytomegalovirus US2 dictates the down-regulation of class I major histocompatibility molecules. J Biol Chem. 2006;281(28):19395–406. doi:10.1074/jbc.M601026200.

    PubMed  CAS  Google Scholar 

  82. Rehm A, Engelsberg A, Tortorella D, Korner IJ, Lehmann I, Ploegh HL, et al. Human cytomegalovirus gene products US2 and US11 differ in their ability to attack major histocompatibility class I heavy chains in dendritic cells. J Virol. 2002;76(10):5043–50.

    PubMed  CAS  Google Scholar 

  83. Tomazin R, Boname J, Hegde NR, Lewinsohn DM, Altschuler Y, Jones TR, et al. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat Med. 1999;5(9):1039–43. doi:10.1038/12478.

    PubMed  CAS  Google Scholar 

  84. Barel MT, Ressing M, Pizzato N, van Leeuwen D, Le Bouteiller P, Lenfant F, et al. Human cytomegalovirus-encoded US2 differentially affects surface expression of MHC class I locus products and targets membrane-bound, but not soluble HLA-G1 for degradation. J Immunol. 2003;171(12):6757–65.

    PubMed  CAS  Google Scholar 

  85. Gewurz BE, Wang EW, Tortorella D, Schust DJ, Ploegh HL. Human cytomegalovirus US2 endoplasmic reticulum-lumenal domain dictates association with major histocompatibility complex class I in a locus-specific manner. J Virol. 2001;75(11):5197–204. doi:10.1128/JVI.75.11.5197-5204.2001.

    PubMed  CAS  Google Scholar 

  86. Barel MT, Pizzato N, van Leeuwen D, Bouteiller PL, Wiertz EJ, Lenfant F. Amino acid composition of alpha1/alpha2 domains and cytoplasmic tail of MHC class I molecules determine their susceptibility to human cytomegalovirus US11-mediated down-regulation. Eur J Immunol. 2003;33(6):1707–16. doi:10.1002/eji.200323912.

    PubMed  CAS  Google Scholar 

  87. Oresic K, Tortorella D. Endoplasmic reticulum chaperones participate in human cytomegalovirus US2-mediated degradation of class I major histocompatibility complex molecules. J Gen Virol. 2008;89(Pt 5):1122–30. doi:10.1099/vir.0.83516-0.

    PubMed  CAS  Google Scholar 

  88. Gewurz BE, Gaudet R, Tortorella D, Wang EW, Ploegh HL, Wiley DC. Antigen presentation subverted: structure of the human cytomegalovirus protein US2 bound to the class I molecule HLA-A2. Proc Natl Acad Sci USA. 2001;98(12):6794–9. doi:10.1073/pnas.121172898.

    PubMed  CAS  Google Scholar 

  89. Story CM, Furman MH, Ploegh HL. The cytosolic tail of class I MHC heavy chain is required for its dislocation by the human cytomegalovirus US2 and US11 gene products. Proc Natl Acad Sci USA. 1999;96(15):8516–21.

    PubMed  CAS  Google Scholar 

  90. Schust DJ, Tortorella D, Seebach J, Phan C, Ploegh HL. Trophoblast class I major histocompatibility complex (MHC) products are resistant to rapid degradation imposed by the human cytomegalovirus (HCMV) gene products US2 and US11. J Exp Med. 1998;188(3):497–503.

    PubMed  CAS  Google Scholar 

  91. Besold K, Frankenberg N, Pepperl-Klindworth S, Kuball J, Theobald M, Hahn G, et al. Processing and MHC class I presentation of human cytomegalovirus pp 65-derived peptides persist despite gpUS2-11-mediated immune evasion. J Gen Virol. 2007;88(Pt 5):1429–39. doi:10.1099/vir.0.82686-0.

    PubMed  CAS  Google Scholar 

  92. Besold K, Wills M, Plachter B. Immune evasion proteins gpUS2 and gpUS11 of human cytomegalovirus incompletely protect infected cells from CD8 T cell recognition. Virology. 2009;391(1):5–19. doi:10.1016/j.virol.2009.06.004.

    PubMed  CAS  Google Scholar 

  93. Vembar SS, Brodsky JL. One step at a time: endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol. 2008;9(12):944–57. doi:10.1038/nrm2546.

    PubMed  CAS  Google Scholar 

  94. Hegde NR, Chevalier MS, Wisner TW, Denton MC, Shire K, Frappier L, et al. The role of BiP in endoplasmic reticulum-associated degradation of major histocompatibility complex class I heavy chain induced by cytomegalovirus proteins. J Biol Chem. 2006;281(30):20910–9. doi:10.1074/jbc.M602989200.

    PubMed  CAS  Google Scholar 

  95. Lilley BN, Ploegh HL. A membrane protein required for dislocation of misfolded proteins from the ER. Nature. 2004;429(6994):834–40. doi:10.1038/nature02592.

    PubMed  CAS  Google Scholar 

  96. Mueller B, Klemm EJ, Spooner E, Claessen JH, Ploegh HL. SEL1L nucleates a protein complex required for dislocation of misfolded glycoproteins. Proc Natl Acad Sci USA. 2008;105(34):12325–30. doi:10.1073/pnas.0805371105.

    PubMed  CAS  Google Scholar 

  97. Mueller B, Lilley BN, Ploegh HL. SEL1L, the homologue of yeast Hrd3p, is involved in protein dislocation from the mammalian ER. J Cell Biol. 2006;175(2):261–70. doi:10.1083/jcb.200605196.

    PubMed  CAS  Google Scholar 

  98. Ye Y, Meyer HH, Rapoport TA. The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature. 2001;414(6864):652–6. doi:10.1038/414652a.

    PubMed  CAS  Google Scholar 

  99. Ye Y, Shibata Y, Yun C, Ron D, Rapoport TA. A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol. Nature. 2004;429(6994):841–7. doi:10.1038/nature02656.

    PubMed  CAS  Google Scholar 

  100. Loureiro J, Lilley BN, Spooner E, Noriega V, Tortorella D, Ploegh HL. Signal peptide peptidase is required for dislocation from the endoplasmic reticulum. Nature. 2006;441(7095):894–7. doi:10.1038/nature04830.

    PubMed  CAS  Google Scholar 

  101. Soetandyo N, Ye Y. The p97 ATPase dislocates MHC class I heavy chain in US2-expressing cells via a Ufd1-Npl4-independent mechanism. J Biol Chem. 2010;285(42):32352–9. doi:10.1074/jbc.M110.131649.

    PubMed  CAS  Google Scholar 

  102. Furman MH, Dey N, Tortorella D, Ploegh HL. The human cytomegalovirus US10 gene product delays trafficking of major histocompatibility complex class I molecules. J Virol. 2002;76(22):11753–6.

    PubMed  CAS  Google Scholar 

  103. Park B, Spooner E, Houser BL, Strominger JL, Ploegh HL. The HCMV membrane glycoprotein US10 selectively targets HLA-G for degradation. J Exp Med. 2010;207(9):2033–41. doi:10.1084/jem.20091793.

    PubMed  CAS  Google Scholar 

  104. Lehner PJ, Karttunen JT, Wilkinson GW, Cresswell P. The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc Natl Acad Sci USA. 1997;94(13):6904–9.

    PubMed  CAS  Google Scholar 

  105. Ahn K, Gruhler A, Galocha B, Jones TR, Wiertz EJ, Ploegh HL, et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity. 1997;6(5):613–21.

    PubMed  CAS  Google Scholar 

  106. Dugan GE, Hewitt EW. Structural and functional dissection of the human cytomegalovirus immune evasion protein US6. J Virol. 2008;82(7):3271–82. doi:10.1128/JVI.01705-07.

    PubMed  CAS  Google Scholar 

  107. Hewitt EW, Gupta SS, Lehner PJ. The human cytomegalovirus gene product US6 inhibits ATP binding by TAP. EMBO J. 2001;20(3):387–96. doi:10.1093/emboj/20.3.387.

    PubMed  CAS  Google Scholar 

  108. Kyritsis C, Gorbulev S, Hutschenreiter S, Pawlitschko K, Abele R, Tampe R. Molecular mechanism and structural aspects of transporter associated with antigen processing inhibition by the cytomegalovirus protein US6. J Biol Chem. 2001;276(51):48031–9. doi:10.1074/jbc.M108528200.

    PubMed  CAS  Google Scholar 

  109. Kim Y, Park B, Cho S, Shin J, Cho K, Jun Y, et al. Human cytomegalovirus UL18 utilizes US6 for evading the NK and T-cell responses. PLoS Pathog. 2008;4(8):e1000123. doi:10.1371/journal.ppat.1000123.

    PubMed  Google Scholar 

  110. Park B, Oh H, Lee S, Song Y, Shin J, Sung YC, et al. The MHC class I homolog of human cytomegalovirus is resistant to down-regulation mediated by the unique short region protein (US)2, US3, US6, and US11 gene products. J Immunol. 2002;168(7):3464–9.

    PubMed  CAS  Google Scholar 

  111. Kim S, Lee S, Shin J, Kim Y, Evnouchidou I, Kim D, et al. Human cytomegalovirus microRNA miR-US4-1 inhibits CD8(+) T cell responses by targeting the aminopeptidase ERAP1. Nat Immunol. 2011;12(10):984–91. doi:10.1038/ni.2097.

    PubMed  CAS  Google Scholar 

  112. Saric T, Chang SC, Hattori A, York IA, Markant S, Rock KL, et al. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol. 2002;3(12):1169–76. doi:10.1038/ni859.

    PubMed  CAS  Google Scholar 

  113. Gilbert MJ, Riddell SR, Plachter B, Greenberg PD. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature. 1996;383(6602):720–2. doi:10.1038/383720a0.

    PubMed  CAS  Google Scholar 

  114. Trgovcich J, Cebulla C, Zimmerman P, Sedmak DD. Human cytomegalovirus protein pp 71 disrupts major histocompatibility complex class I cell surface expression. J Virol. 2006;80(2):951–63. doi:10.1128/JVI.80.2.951-963.2006.

    PubMed  CAS  Google Scholar 

  115. Gallina A, Simoncini L, Garbelli S, Percivalle E, Pedrali-Noy G, Lee KS, et al. Polo-like kinase 1 as a target for human cytomegalovirus pp 65 lower matrix protein. J Virol. 1999;73(2):1468–78.

    PubMed  CAS  Google Scholar 

  116. Browne EP, Shenk T. Human cytomegalovirus UL83-coded pp 65 virion protein inhibits antiviral gene expression in infected cells. Proc Natl Acad Sci USA. 2003;100(20):11439–44. doi:10.1073/pnas.1534570100.

    PubMed  CAS  Google Scholar 

  117. Odeberg J, Plachter B, Branden L, Soderberg-Naucler C. Human cytomegalovirus protein pp 65 mediates accumulation of HLA-DR in lysosomes and destruction of the HLA-DR alpha-chain. Blood. 2003;101(12):4870–7. doi:10.1182/blood-2002-05-1504.

    PubMed  CAS  Google Scholar 

  118. Khan N, Bruton R, Taylor GS, Cobbold M, Jones TR, Rickinson AB, et al. Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes. J Virol. 2005;79(5):2869–79. doi:10.1128/JVI.79.5.2869-2879.2005.

    PubMed  CAS  Google Scholar 

  119. Hansen SG, Powers CJ, Richards R, Ventura AB, Ford JC, Siess D, et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science. 2010;328(5974):102–6. doi:10.1126/science.1185350.

    PubMed  CAS  Google Scholar 

  120. Lemmermann NA, Bohm V, Holtappels R, Reddehase MJ. In vivo impact of cytomegalovirus evasion of CD8 T-cell immunity: facts and thoughts based on murine models. Virus Res. 2011;157(2):161–74. doi:10.1016/j.virusres.2010.09.022.

    PubMed  CAS  Google Scholar 

  121. Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature. 1988;331(6153):269–72. doi:10.1038/331269a0.

    PubMed  CAS  Google Scholar 

  122. Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity. 1997;7(2):273–82.

    PubMed  CAS  Google Scholar 

  123. Kubin M, Cassiano L, Chalupny J, Chin W, Cosman D, Fanslow W, et al. ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur J Immunol. 2001;31(5):1428–37. doi:10.1002/1521-4141(200105)31:5<1428:AID-IMMU1428>3.0.CO;2-4.

    PubMed  CAS  Google Scholar 

  124. Welte SA, Sinzger C, Lutz SZ, Singh-Jasuja H, Sampaio KL, Eknigk U, et al. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol. 2003;33(1):194–203. doi:10.1002/immu.200390022.

    PubMed  CAS  Google Scholar 

  125. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med. 1998;187(5):813–8.

    PubMed  CAS  Google Scholar 

  126. Braud VM, Allan DS, O’Callaghan CA, Soderstrom K, D’Andrea A, Ogg GS, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391(6669):795–9. doi:10.1038/35869.

    PubMed  CAS  Google Scholar 

  127. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA. 1998;95(9):5199–204.

    PubMed  CAS  Google Scholar 

  128. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9(5):495–502. doi:10.1038/ni1581.

    PubMed  CAS  Google Scholar 

  129. Orange JS, Fassett MS, Koopman LA, Boyson JE, Strominger JL. Viral evasion of natural killer cells. Nat Immunol. 2002;3(11):1006–12. doi:10.1038/ni1102-1006.

    PubMed  CAS  Google Scholar 

  130. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod’homme V, Aicheler R, et al. Modulation of natural killer cells by human cytomegalovirus. J Clin Virol. 2008;41(3):206–12. doi:10.1016/j.jcv.2007.10.027.

    PubMed  CAS  Google Scholar 

  131. Chang WL, Baumgarth N, Yu D, Barry PA. Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality. J Virol. 2004;78(16):8720–31. doi:10.1128/JVI.78.16.8720-8731.2004.

    PubMed  CAS  Google Scholar 

  132. Jenkins C, Abendroth A, Slobedman B. A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection. J Virol. 2004;78(3):1440–7.

    PubMed  CAS  Google Scholar 

  133. Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci USA. 2000;97(4):1695–700.

    PubMed  CAS  Google Scholar 

  134. Raftery MJ, Wieland D, Gronewald S, Kraus AA, Giese T, Schonrich G. Shaping phenotype, function, and survival of dendritic cells by cytomegalovirus-encoded IL-10. J Immunol. 2004;173(5):3383–91.

    PubMed  CAS  Google Scholar 

  135. Spencer JV, Lockridge KM, Barry PA, Lin G, Tsang M, Penfold ME, et al. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol. 2002;76(3):1285–92.

    PubMed  CAS  Google Scholar 

  136. Slobedman B, Mocarski ES, Arvin AM, Mellins ED, Abendroth A. Latent cytomegalovirus down-regulates major histocompatibility complex class II expression on myeloid progenitors. Blood. 2002;100(8):2867–73. doi:10.1182/blood.V100.8.2867.

    PubMed  CAS  Google Scholar 

  137. Cheung AK, Gottlieb DJ, Plachter B, Pepperl-Klindworth S, Avdic S, Cunningham AL, et al. The role of the human cytomegalovirus UL111A gene in down-regulating CD4+ T-cell recognition of latently infected cells: implications for virus elimination during latency. Blood. 2009;114(19):4128–37. doi:10.1182/blood-2008-12-197111.

    PubMed  CAS  Google Scholar 

  138. Gredmark S, Soderberg-Naucler C. Human cytomegalovirus inhibits differentiation of monocytes into dendritic cells with the consequence of depressed immunological functions. J Virol. 2003;77(20):10943–56.

    PubMed  CAS  Google Scholar 

  139. Rolle A, Olweus J. Dendritic cells in cytomegalovirus infection: viral evasion and host countermeasures. APMIS. 2009;117(5–6):413–26. doi:10.1111/j.1600-0463.2009.02449.x.

    PubMed  CAS  Google Scholar 

  140. Carlier J, Martin H, Mariame B, Rauwel B, Mengelle C, Weclawiak H, et al. Paracrine inhibition of GM-CSF signaling by human cytomegalovirus in monocytes differentiating to dendritic cells. Blood. 2011;118(26):6783–92. doi:10.1182/blood-2011-02-337956.

    PubMed  Google Scholar 

  141. Frascaroli G, Varani S, Mastroianni A, Britton S, Gibellini D, Rossini G, et al. Dendritic cell function in cytomegalovirus-infected patients with mononucleosis. J Leukoc Biol. 2006;79(5):932–40. doi:10.1189/jlb.0905499.

    PubMed  CAS  Google Scholar 

  142. Kvale EO, Dalgaard J, Lund-Johansen F, Rollag H, Farkas L, Midtvedt K, et al. CD11c+ dendritic cells and plasmacytoid DCs are activated by human cytomegalovirus and retain efficient T cell-stimulatory capability upon infection. Blood. 2006;107(5):2022–9. doi:10.1182/blood-2005-05-2016.

    PubMed  CAS  Google Scholar 

  143. Reeves MB, Compton T. Inhibition of inflammatory interleukin-6 activity via extracellular signal-regulated kinase-mitogen-activated protein kinase signaling antagonizes human cytomegalovirus reactivation from dendritic cells. J Virol. 2011;85(23):12750–8. doi:10.1128/JVI.05878-11.

    PubMed  CAS  Google Scholar 

  144. Shamu CE, Flierman D, Ploegh HL, Rapoport TA, Chau V. Polyubiquitination is required for US11-dependent movement of MHC class I heavy chain from endoplasmic reticulum into cytosol. Mol Biol Cell. 2001;12(8):2546–55.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

DT is supported by an American Heart Association Grant, DTRA contract # W81XWH-10-2-0048, and the Irma T. Hirschl Trust. VN is a post-doctoral trainee supported by the USPHS Institutional Research Training Award T32-AI078892. VR is a pre-doctoral trainee supported in part by an USPHS Institutional Research Training Award T32-AI07647 and the Kadlec Medical Center Foundation. TG is a pre-doctoral trainee supported in part by an USPHS Institutional Research Training Award T32-AI07647 and a Helmsley Fellowship.

Author information

Authors and Affiliations

  1. Department of Microbiology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1124, New York, NY, 10029, USA

    Vanessa Noriega, Veronika Redmann, Thomas Gardner & Domenico Tortorella

Authors
  1. Vanessa Noriega
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Veronika Redmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Gardner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Domenico Tortorella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Domenico Tortorella.

Additional information

Vanessa Noriega, Veronika Redmann, Thomas Gardner contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Noriega, V., Redmann, V., Gardner, T. et al. Diverse immune evasion strategies by human cytomegalovirus. Immunol Res 54, 140–151 (2012). https://doi.org/10.1007/s12026-012-8304-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-012-8304-8

Keywords

Search

Navigation